Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
VERV.US
id: 436

Verve Therapeutics (VERV) Trial Halt Case

D. Massachusetts
Court
1:24-cv-12218
Case number
09 Aug 2022
Class period Start
01 Apr 2024
Class period End
28 Oct 2024
Lead Plaintiff motion deadline
  • $VERV stockholders filed a claim against Verve for misleading them about the Heart-1 trial halt and overstating the benefits of their LNP delivery system.
  • After the news on April 2, 2024, $VERV dropped by over 34%.
  • Verve investors can join this case to be notified about potential recovery.
Case Details:

On November 7, 2022, Verve announced that the FDA placed a hold on the company's Investigational New Drug application, halting a potential clinical trial for VERVE-101 to treat patients with heterozygous familial hypercholesterolemia.

Then, on April 2, 2024, Verve Therapeutics announced that the Heart-1 trial would be stopped.

The halt was due to a problem with the LNP delivery system after a patient received 0.45 mg/kg of VERVE-101.

On this news, $VERV fell by 34.9% on April 2, 2024.

Based on these events, $VERV investors filed a claim against Verve, accusing the company of the following:
  • Verve failed to fully disclose why the Heart-1 trial was halted.
  • They also overstated the benefits of their LNP delivery system.
Considering all the representations, investors suspect Verve misled them about why the Heart-1 trial was halted and exaggerated the benefits of their LNP delivery system.
Case Status
Lead Plaintiff Submission
Alleged Offence
Misleading Statements
Failure to Disclose
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Government Authority
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
07 November 2022
Filing date
27 August 2024
Lead Plaintiff Deadline
28 October 2024
Collecting participants…